Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 15/20 | 0.47 |
| ▸ | HTR1A | P08908 | 14/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.46 |
| ▸ | HTR7 | P34969 | 14/20 | 0.46 |
| ▸ | HTR6 | P50406 | 14/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phthalic Acid SCHEMBL9045536 | 1.00 | OPRM1 (0.53) | OPRM1OPRK1DRD2HTR1ASLC6A4 | |
| Phthalic Acid SCHEMBL9045679 | 0.83 | OPRM1 (0.51) | OPRM1OPRK1DRD2HTR1ASLC6A4 | |
| Phthalic Acid SCHEMBL30909062 | 0.83 | OPRM1 (0.51) | OPRM1OPRK1DRD2HTR1ASLC6A4 | |
| SCHEMBL7458881 | 0.78 | OPRM1 (0.58) | OPRM1OPRK1DRD2HTR1ASLC6A4 | |
| SCHEMBL7465475 | 0.76 | HTR1A (0.57) | OPRM1OPRK1DRD2HTR1A | |
| Tepirindole SCHEMBL635174 | 0.72 | SLC6A4 (0.72) | OPRM1OPRK1DRD2HTR1ASLC6A4 | |
| Tepirindole SCHEMBL29710897 | 0.72 | SLC6A4 (0.72) | OPRM1OPRK1DRD2HTR1ASLC6A4 | |
| Tepirindole SCHEMBL11307437 | 0.72 | SLC6A4 (0.72) | OPRM1OPRK1DRD2HTR1ASLC6A4 | |
| SCHEMBL14280720 | 0.71 | OPRM1 (1.00) | OPRM1OPRK1DRD2HTR1ASLC6A4 | |
| SCHEMBL7455854 | 0.70 | HTR1A (0.60) | OPRM1OPRK1DRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ LP (CA) | 2026-05-07 | — | — | US | disclosed |
| WO-2024073845-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ, LIMITED PARTNERSHIP (CA) | 2024-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | HTR1F, HTR1A, HTR1D | OPRM1 218/4885OPRK1 266/4885DRD2 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.